Intact Investment Management Inc. Decreases Position in Amgen Inc. $AMGN

Key Points

• Intact Investment Management Inc. cut its position in Amgen by 31.7% in Q4, selling 7,100 shares and finishing with 15,300 shares worth about $5.008 million.
• Amgen beat quarterly expectations with $5.15 EPS (vs. $4.77 est.) and $8.62 billion in revenue (vs. $8.58B est.), and set FY2026 EPS guidance of 21.700–23.100 (consensus ~22.28).
• Amgen announced a quarterly dividend of $2.52 (annualized $10.08), with an ex-dividend date of May 15 and a yield of about 3.1%.

Intact Investment Management Inc. lessened its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 31.7% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 15,300 shares of the medical research company's stock after selling 7,100 shares during the period. Intact Investment Management Inc.'s holdings in Amgen were worth $5,008,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Montag A & Associates Inc. raised its position in Amgen by 3.8% in the 4th quarter. Montag A & Associates Inc. now owns 2,976 shares of the medical research company's stock valued at $974,000 after purchasing an additional 108 shares in the last quarter. Hoya Capital Real Estate LLC acquired a new position in shares of Amgen during the fourth quarter worth about $218,000. Core Alternative Capital grew its position in shares of Amgen by 9.2% during the fourth quarter. Core Alternative Capital now owns 3,653 shares of the medical research company's stock worth $1,196,000 after buying an additional 308 shares in the last quarter. Woodard & Co. Asset Management Group Inc. ADV grew its position in shares of Amgen by 10.9% during the fourth quarter. Woodard & Co. Asset Management Group Inc. ADV now owns 11,697 shares of the medical research company's stock worth $3,828,000 after buying an additional 1,154 shares in the last quarter. Finally, Oak Harbor Wealth Partners LLC grew its position in shares of Amgen by 3.7% during the fourth quarter. Oak Harbor Wealth Partners LLC now owns 4,398 shares of the medical research company's stock worth $1,440,000 after buying an additional 156 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company's stock.

Amgen Price Performance

Shares of AMGN opened at $323.85 on Tuesday. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $391.29. The stock has a market cap of $174.78 billion, a PE ratio of 22.54, a price-to-earnings-growth ratio of 3.24 and a beta of 0.44. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 0.90. The firm has a fifty day moving average price of $358.07 and a 200 day moving average price of $341.12.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating analysts' consensus estimates of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm had revenue of $8.62 billion during the quarter, compared to analysts' expectations of $8.58 billion. During the same period in the previous year, the company earned $4.90 earnings per share. Amgen's quarterly revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, sell-side analysts anticipate that Amgen Inc. will post 22.28 EPS for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be paid a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 3.1%. Amgen's payout ratio is currently 70.15%.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on AMGN shares. Mizuho lifted their price objective on shares of Amgen from $280.00 to $295.00 and gave the stock an "outperform" rating in a research report on Tuesday, February 10th. Guggenheim decreased their price objective on shares of Amgen from $351.00 to $340.00 and set a "neutral" rating for the company in a research report on Monday. Freedom Capital cut shares of Amgen from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 12th. Oppenheimer set a $400.00 price objective on shares of Amgen and gave the stock an "outperform" rating in a research report on Thursday, January 29th. Finally, Leerink Partners reaffirmed a "market perform" rating and set a $355.00 price objective on shares of Amgen in a research report on Thursday, March 5th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $357.12.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen announced an additional $300 million investment to expand and modernize its U.S. manufacturing footprint in Juncos, Puerto Rico — part of nearly $2 billion of U.S. manufacturing investment over the last year; this strengthens capacity, supply resilience and long-term revenue support. AMGEN ANNOUNCES ADDITIONAL $300 MILLION U.S. MANUFACTURING INVESTMENT, TOTALING NEARLY $2 BILLION OVER THE LAST YEAR
• Neutral Sentiment: Coverage of the Puerto Rico expansion by major outlets (Reuters, Quartz) highlights the same investment news — useful for validation but not new catalyst beyond the company release. Amgen to invest additional $300 million to boost US manufacturing footprint
• Neutral Sentiment: Health-care stocks were softer in afternoon trade, which can amplify selling in large-cap biopharma names like Amgen even when company fundamentals are unchanged. Sector Update: Health Care Stocks Softer in Afternoon Trading
• Neutral Sentiment: A Zacks note flagged increased investor attention to AMGN; this signals higher scrutiny/flow but doesn’t itself imply directional catalyst. Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
• Negative Sentiment: Guggenheim trimmed its price target on AMGN to $340 from $351 and kept a Neutral rating — a modest cut but enough to pressure sentiment because it lowers upside expectations versus recent levels. Guggenheim Trims Amgen Price Target to $340: Is the Biotech Giant Losing Its Edge?

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.